Stanescu Nir, Khalifa Khaled, Arnon Roee, Rabina Gilad, Nemet Arie Y, Arbel Itamar, Geffen Noa, Segal Ori
Department of Ophthalmology, Assuta Samson Hospital, Ashdod, Israel.
Faculty of Medicine, Ben-Gurion University of the Negev, Be'er Sheva, Israel.
Eye (Lond). 2025 Apr 15. doi: 10.1038/s41433-025-03792-4.
To investigate the prognostic significance of optical density ratio (ODR) of intraretinal fluid (IRF) on best corrected visual acuity (deltaBCVA) in patients with neovascular age-related macular degeneration (nAMD) treated with anti-vascular endothelial growth factor (VEGF) agents.
In this retrospective study, optical coherence tomography (OCT) scans of treatment-naïve eyes with nAMD treated with anti-VEGF injections were reviewed. ODR of retinal fluid compartments was calculated using strict and flexible methods in each OCT image. We used linear mixed models to investigate the relationship between ODR values on OCT and deltaBCVA after 36 months of follow up.
We included 86 eyes of 78 patients. We found negative associations between strict ODR of IRF (p = 0.02; coef. -0.05, 95% CI -0.10, -0.01), and flexible ODR of IRF (p = 0.03; coef. -0.05, 95% CI -0.10, -0.01), and deltaBCVA after 36 months. ODR of SRF and PED were not significantly associated with deltaBCVA.
This is the largest study to investigate the relationship between ODR in nAMD patients and deltaBCVA. Eyes with higher ODR values of IRF are less likely to have a deterioration in BCVA over 36 months of follow up. ODR could be used as another OCT prognostic biomarker for BCVA in nAMD patients.
探讨抗血管内皮生长因子(VEGF)药物治疗的新生血管性年龄相关性黄斑变性(nAMD)患者视网膜内液(IRF)的光密度比(ODR)对最佳矫正视力(BCVA变化量)的预后意义。
在这项回顾性研究中,对接受抗VEGF注射治疗的初治nAMD患眼的光学相干断层扫描(OCT)图像进行了回顾。在每张OCT图像中,使用严格和灵活的方法计算视网膜液腔的ODR。我们使用线性混合模型研究随访36个月后OCT上的ODR值与BCVA变化量之间的关系。
我们纳入了78例患者的86只眼。我们发现,36个月后,IRF的严格ODR(p = 0.02;系数 -0.05,95%可信区间 -0.10,-0.01)和IRF的灵活ODR(p = 0.03;系数 -0.05,95%可信区间 -0.10,-0.01)与BCVA变化量呈负相关。视网膜下液(SRF)和色素上皮脱离(PED)的ODR与BCVA变化量无显著相关性。
这是研究nAMD患者ODR与BCVA变化量之间关系的最大规模研究。IRF的ODR值较高的患眼在36个月的随访中BCVA恶化的可能性较小。ODR可作为nAMD患者BCVA的另一个OCT预后生物标志物。